News | News By Subject | News by Disease News By Date | Search News

Hemophilia B News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
SoCal's Arrowhead Pharma (ARWR) Stock Craters After Terminating 30% of Workforce, Discontinuing Work on Lead Hep B Drugs     12/1/2016
Shire (SHPG) Kills Baxalta (BXLT)'s Hemophilia B Program; Clears Path for BioMarin (BMRN), Spark Therapeutics (ONCE) and uniQure (QURE)     8/4/2016
FDA Calls Pfizer (PFE), Spark Therapeutics (ONCE)'s Hemophilia B Drug a Breakthrough     7/22/2016
Sources Reveal Biogen (BIIB) is Exploring Sale of Hemophilia Assets     4/12/2016
Pfizer (PFE)'s Hemophilia B Drug Cuts Bleeding in Late-Stage Study     3/9/2016
FDA Green Lights CSL Behring's Idelvion for Hemophilia B     3/7/2016
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review     3/17/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Spark Therapeutics Strikes $280 Million Hemophilia B Pact With Pfizer (PFE)     12/9/2014
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Baxter International, Inc. (BAX) Opens Its First State-Of-The-Art Biologics Facility In Asia     8/11/2014
Pfizer Inc. (PFE) Hemophilia B Treatment Regimen Meets Endpoint In Phase 3 Trial     7/16/2014
FDA Approves Biogen Idec, Inc. (Massachusetts) (BIIB)'s Hemophilia B Drug Alprolix     3/31/2014
Baxter International, Inc. (BAX) Receives FDA Approval Of FEIBA [Anti-Inhibitor Coagulant Complex] For Prophylactic Treatment Of Hemophilia A&B Patients With Inhibitors     12/19/2013

News from Around the Web

Press Releases
CSL Behring Presents New Phase III Analysis Of IDELVION For Hemophilia B At The 2016 American Society of Hematology Annual Meeting     12/5/2016
Children's Hospital of Philadelphia Release: After One Dose Of Gene Therapy, Hemophilia B Patients Maintain Near-Normal Levels Of Clotting Factor     12/5/2016
American Society of Hematology Release: Bioengineering Innovations Show Promise For Improving Treatments And Drug Delivery     12/5/2016
uniQure (QURE) Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B     12/5/2016
Alnylam (ALNY) Reports Positive Interim Clinical Results For Fitusiran From Ongoing Phase 2 Open Label Extension Study In Patients With Hemophilia A Or B Without Inhibitors     12/5/2016
Swedish Orphan Biovitrum: Alprolix Approved In Switzerland For The Treatment Of Hemophilia B     10/28/2016
China Biologic Products Receives CFDA Clinical Trial Approval For Human Coagulation Factor IX     9/19/2016
Sangamo (SGMO) Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing     9/6/2016
uniQure (QURE) Presents Updated Clinical Data In Patients With Severe Hemophilia B Demonstrating Up To 9 Months Of Sustained Levels Of Factor IX Activity And Therapeutic Effect     7/28/2016
Novo Nordisk A/S (NVO) Announces New Data On Psychosocial Impact Of People Living With Hemophilia B     7/26/2016
Alnylam (ALNY) To Report New Clinical Results With Fitusiran At The World Federation of Hemophilia 2016 World Congress     7/25/2016
CSL Behring To Present New Data For IDELVION And AFSTYLA At The World Federation of Hemophilia 2016 World Congress     7/19/2016
Biogen (BIIB) And Sobi To Showcase Long-Term Efficacy And Safety Data From Extended Half-Life Hemophilia Therapies At World Federation Of Hemophilia 2016 World Congress     7/18/2016
uniQure (QURE) Presents Clinical Data From Ongoing Phase I/II Study In Hemophilia B Demonstrating 6 Months Of Sustained Increases In Factor IX Activity     6/13/2016
uniQure (QURE) Announces Oral Presentation Of Clinical Data From Ongoing Phase I/II Study Of AMT-060 In Hemophilia B At The 21st Congress Of The European Hematology Association     5/19/2016

//-->